The Wall Street Journal’s Venture Capital Pro quoted a recent biopharma report from William Blair’s equity capital markets team, noting the uptick in activity for PIPEs among biopharma companies in 2023.
Investment Banking
Equity Capital Markets Team Quoted by The Wall Street Journal
Delivered to Your Inbox
Stay up-to-date with the latest William Blair news and insights
Our Latest News
Duomed Has Entered Into Exclusive Negotiations to be Acquired by Palex
William Blair acted as the exclusive financial advisor to Duomed Group, a portfolio company of G Square Healthcare Private Equity, in connection with the contemplated sale to Palex Medical, a portfolio company of Apax Partners and Fremman Capital.
Read moreCMMC 2.0 Set to Materially Expand Cyber and Regulatory Compliance Market
The 220,000+ companies that contract with the Department of Defense will soon face a significantly expanded regulatory framework—known as CMMC 2.0—designed to thwart increased cyber threats and secure the defense industrial base.
Read moreTT medic has Agreed to Partner with Trill Impact
William Blair acted as the exclusive financial advisor to TT medic GmbH and its shareholders in connection with entering a partnership with Trill Impact.
Read more